Johnson & Johnson: Single Infusion of Carvykti Delivered Five-year Treatment-free Remissions in 50% of Patients in Early Line Relapsed/refractory Multiple Myeloma
September 26, 2026
September 26, 2026
RARITAN, New Jersey, Sept. 26 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Single infusion of CARVYKTI(R) (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
* New results suggest earlier treatment may increase the likelihood of long-term remission
* Study adds to Johnson & Johnson's overwhelming body of ev . . .
* * *
Single infusion of CARVYKTI(R) (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
* New results suggest earlier treatment may increase the likelihood of long-term remission
* Study adds to Johnson & Johnson's overwhelming body of ev . . .